Feeds:
Posts
Comments

Posts Tagged ‘solanezumab’

The AP (5/21) reported, “Eli Lilly & Co. said Thursday it will start late-stage clinical testing of an Alzheimer’s disease” medication candidate, solanezumab, “with enrollment of patients scheduled to begin this month.” The medication “candidate is intended to prevent the progression of mild to moderate Alzheimer’s disease,” and Lilly plans “two separate late-stage trials, which will involve a total of 2,000 patients age 55 and older.” The trials will involve patients taking “a 400 mg infusion of solanezumab or a placebo once every four weeks” for 18 months, and will “test whether solanezumab is better than the placebo at slowing the mental and functional decline of Alzheimer’s patients.”

The Indianapolis Star (5/21, Spalding) added that patients in the “separate but identical” Expedition trials will be “from 16 countries, including the US.” The company “also is in the process of testing out a different type of Alzheimer’s treatment, also geared to help those with the disease, which is known to cause dementia.” Eric Siemers, MD, medical director for Lilly’s Alzheimer’s disease research, said, “Biomarker results from a phase II solanezumab trial give us hope that Lilly is on a path toward a treatment that may slow the rate of progression of Alzheimer’s disease.”

       

According to Reuters (5/22), both of the medicines that Lilly is testing target amyloid beta protein fragments in the brain that are believed to be linked to Alzheimer’s.

Read Full Post »